ZTSNYQHealthcare·Drug Manufacturers - Specialty & Generic#2 in industry

Zoetis Inc.

Reports in 10d· 2026-05-07

-5.1% · 90d

$118.64

+1.77 (+1.51%)

News

No News Yet

Press releases and SEC filings for ZTS will appear here as they are published.

Check back later for updates

Key Data

Market Cap$50.08B

Open$116.62

Prev Close$116.87

Day Range$116.60 – $119.68

52W Range$113.29 – $172.23

Volume1,496,927

P/E (TTM)19.71

EPS$6.02

Dividend Yield1.81%

Beta0.97

Profit Margin28.23%

Revenue Growth3.00%

Price Target$150.29(+26.7%)

Next Earnings2026-05-07(10d)

Analyst Ratings

Buy20 analysts

Buy 12Hold 8Sell 0

About

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Healthcare · Drug Manufacturers - Specialty & Generic

14,500 employees

www.zoetis.com